Satellite Banner
Technology Networks Header
Wednesday, October 01, 2014
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
How to Make Stronger, “Greener” Cement
Analysis of material’s molecular structure leads to a new formula that could cut greenhouse-gas emissions.
Chemists Recruit Anthrax to Deliver Cancer Drugs
With some tinkering, a deadly protein becomes an efficient carrier for antibody drugs.
Biologists Find An Early Sign Of Cancer
Patients show boost in certain amino acids years before diagnosis of pancreatic cancer.
Researchers Develop New DNA Sequencing Method to Diagnose Tuberculosis
Teams aim to test the metagenomics technique on a wide range of samples.
UW-Madison Team Developing ‘Tissue Chip’ to Screen Neurological Toxins
A faster, more affordable way to screen for neural toxins.
A Novel Method for Portable Detection of Potent Drugs Known as ‘Bath Salts’
Researchers developed a low-cost, disposable and rapid platform for detecting bath salts.
Protein ‘Map’ Could Lead to Potent New Cancer Drugs
Findings will help scientists to design drugs that could target NMT enzyme.
Research Shows Alcohol Sensations Influenced by Genes
The research was the first to consider whether variation in the burn receptor gene might influence alcohol sensations.
Monkey Antibodies Help Fight Virus
Details of monkey antibodies against chikungunya virus could help to fight the disease in humans.
Protecting the Body from Itself
Scientists advance understanding of autoimmunity with discovery of link between major immune cell types.
Scroll Up
Scroll Down
Return
The Versatility of Fragment Screening Approaches and the Application of Fragment Binding Information in Durg Discovery
Stefan Geschwindner, AstraZeneca, speaking at Discovery Chemistry Congress 2012.
Date Posted: Friday, November 23, 2012
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



AstraZeneca Buys Rights to Almirall Respiratory Franchise
AstraZeneca agrees an initial consideration of $875 million on completion, which may rise to $1.22 billion in development, launch, and sales-related milestones.
Monday, August 04, 2014
AstraZeneca Reveals Designs for Cambridge Headquarters
Company revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK.
Friday, July 18, 2014
AstraZeneca system implemented with input from Tessella wins 2014 Bio-IT World Best Practices Award
Award winning Clinical & Health IT system allows AstraZeneca to respond rapidly to safety concerns and swiftly identify risk factors for adverse events, protecting trial participants while rescuing trials from costly late-stage failure.
Saturday, May 10, 2014
AstraZeneca Board Rejects Pfizer Proposal
The financial and other terms of the proposal have been described as inadequate, substantially undervaluing AstraZeneca.
Friday, May 02, 2014
AstraZeneca to Acquire Bristol-Myers Squibb Share of Global Diabetes Alliance Assets
Global agreement strengthens AstraZeneca’s commitment to diabetes.
Monday, December 23, 2013
AstraZeneca to Invest £120 Million in New Manufacturing Facility
AstraZeneca invests to continue production of Zoladex, an injectable treatment for patients with prostate cancer.
Tuesday, November 12, 2013
AstraZeneca to Acquire Pearl Therapeutics to Strengthen Respiratory Portfolio
Pearl Therapeutics is focused on the development of inhaled small-molecule therapeutics for respiratory disease.
Wednesday, June 12, 2013
AstraZeneca to Acquire Omthera Pharmaceuticals
Acquisition includes the take-over of NDA-ready novel dyslipidemia treatment to complement cardiovascular portfolio.
Wednesday, May 29, 2013
AstraZeneca and BMS Receive Award from Major Medical Association
Companies received the American College of Endocrinology (ACE) Philanthropic Award at the AACE 22nd Annual Scientific & Clinical Congress in Phoenix, Arizona on May 4, 2013.
Thursday, May 09, 2013
AstraZeneca’s Biologics Unit Acquires AlphaCore Pharma
AlphaCore Pharma is a biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase enzyme.
Wednesday, April 03, 2013
AstraZeneca Announces Changes to Senior Executive Team
Company’s President and Executive Vice President will leave the company at the end of January.
Monday, January 28, 2013
Ten Pharmaceutical Companies Unite
Ten leading biopharmaceutical companies announced that they have formed a non-profit organization to accelerate the development of new medicines.
Wednesday, September 26, 2012
AstraZeneca and the Broad Institute Collaborate
Partnership to advance discovery of antibacterial and antiviral agents.
Tuesday, September 11, 2012
AstraZeneca Appoints Pascal Soriot CEO
Pascal Soriot will take on his new responsibilities and join the AstraZeneca PLC Board as an Executive Director on 1 October 2012.
Tuesday, August 28, 2012
AstraZeneca to Provide UK Academics with Access to Compound Library
Their groundbreaking new collaboration with the Medical Research Council (MRC) will see the company providing the UK academic sector with access to 22 drugs.
Friday, December 09, 2011
 
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv